K-161 is under clinical development by Kowa and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how K-161’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
K-161 is under development for the treatment of dry eye (keratoconjunctivitis sicca). It is administered by ophthalmic route as a solution.
Kowa is a pharmaceutical company which is involved into the business related to the manufacturing and selling of therapeutic drugs, medical devices, energy-saving products. It imports and exports LED lighting equipment, optical equipment and renewable energy power generation systems; and trading of textile, lifestyle products, construction materials, machinery, chemicals, and commodities. The company also trades various items, such as pharmaceutical ingredients, ingredients for cosmetics, monomers and specialty chemicals, oil and fats, feed additives, activated carbon and coal, industrial machinery and equipment and vessels. The company operates through its subsidiaries and affiliates across Japan, North America, Latin America, Europe, and Asia. Kowa is headquartered in Nagoya, Aichi, Japan.
For a complete picture of K-161’s drug-specific PTSR and LoA scores, buy the report here.